IGI Logo

We hosted Mr. Vikram Vuppala, Founder Chairman & Managing Director, Nephrocare Health Services, for a panel discussion as part of our CEO track session at AGIC 2025. Here are the key takeaways of the session:

Industry perspective: Long runway driven by low organized penetration

NephroPlus: Dialysis remains one of the most underpenetrated chronic-care segments, with only ~15% of patients requiring dialysis currently receiving treatment. Organized penetration stands at ~20%, with NephroPlus accounting for majority of the overall market. The significant unmet demand provides a multidecade growth runway, while GLP-1 therapies are unlikely to materially impact demand, given the large untreated patient pool. Mr. Vikram also indicated that the company does not foresee any meaningful macroeconomic challenges across its operating geographies.

ASG Eye Hospitals: Organized eye care in India remains at an early stage, comparable to China's market in the mid-2000s. Rising insurance penetration, improving healthcare awareness, favorable demographics, and increasing government support through schemes such as Ayushman Bharat are expected to accelerate the shift toward organized providers. Dr. Arun also noted that increasing screen time and changing lifestyles are expected to drive a meaningful rise in myopia over the coming decades. While refractive procedures currently contribute less than 5% of revenues, they are expected to become an important long-term growth driver.

Competitive advantage: Scale and specialization

NephroPlus: Dialysis is a scale-driven business where profitability requires both large network size and complete operational focus. Dialysis contributes less than 1% of revenues for most multispecialty hospitals, limiting their incentive to optimize the business as hospitals primarily derive value from downstream referrals rather than dialysis itself. Dedicated chains benefit from superior procurement, technician training, equipment management, and lean operating structures that hospitals find difficult to replicate. Medical consumables remain the single largest cost component in dialysis, making procurement scale a key competitive advantage.

ASG Eye Hospitals: Eye care has transitioned from an inpatient service to a predominantly day-care specialty due to technological advancements. Dedicated eye hospitals benefit from lower capex, lower operating costs, no dependence on bed occupancy, and better infection control. Specialized infrastructure and workflow create meaningful advantages for focused single-specialty providers over multi-specialty hospitals.

Focused approach: Disciplined expansion backed by superior execution

NephroPlus: International revenue contribution has increased from ~10% historically to ~45% currently. Overseas expansion began six years ago with the company's first acquisition in the Philippines following nearly two years of market evaluation. The company follows a dual acquisition strategy comprising standalone clinics and regional chains, with the first acquisition in a new country requiring the greatest legal and operational effort before subsequent expansion becomes more efficient.

ASG Eye Hospitals: The Vasan acquisition was completed following extensive due diligence across almost every clinic. Infrastructure upgrades, equipment replacement, and organizational restructuring were completed over 6-9 months. Monthly revenues have increased nearly five-fold, from approximately INR100m at acquisition to around INR500m currently.

Patient-first approach remains the key motto

NephroPlus: Patient outcomes remain the primary focus, with financial performance viewed as a by-product of sustainable execution.

ASG Eye Hospitals: The company follows a doctor-centric operating model, with physicians provided significant clinical autonomy and treated as long-term partners. Discussions remain focused on clinical outcomes, patient care, and infrastructure rather than commercial targets, supporting strong doctor retention.

For More Research Reports : Click Here 

For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412